We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SRG:MILSnam S.p.A. Analysis

Data as of 2026-03-13 - not real-time

€6.61

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The stock is trading above its short‑ and long‑term moving averages, confirming a bullish technical backdrop. Momentum indicators show the RSI in the upper mid‑range and the MACD line hovering just below its signal, hinting at a cautious optimism. Volume has been on the rise, supporting the price advance, while the beta is exceptionally low, suggesting limited market‑wide volatility. The recent Goldman Sachs upgrade to a buy further reinforces the positive short‑term sentiment.
Fundamentally, the company delivers robust profitability with double‑digit revenue growth and margins that outpace many peers. A generous dividend yield attracts income investors, yet the payout ratio approaches three‑quarters of earnings and the balance sheet carries a very high debt‑to‑equity ratio, raising questions about long‑term sustainability. Free cash flow is currently neutral, and the lack of cash reserves adds to leverage concerns. However, the price‑to‑earnings multiple sits well below the industry average and the discounted cash‑flow model points to a material upside, positioning the stock as potentially undervalued despite the debt load.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical positioning above key moving averages
  • Approaching resistance level with bearish MACD divergence
  • Attractive dividend yield for income focus

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF valuation indicating upside potential
  • Strong operating margins and revenue growth
  • Analyst upgrade signaling improved outlook

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and limited free cash flow
  • Regulated utility business providing stable cash flows
  • Dividend sustainability concerns amid debt load

Key Metrics & Analysis

Financial Health

Revenue Growth13.30%
Profit Margin36.60%
P/E Ratio16.5
ROE15.55%
ROA3.60%
Debt/Equity188.72
P/B Ratio2.3
Op. Cash Flow€2.7B
Industry P/E23.3

Technical Analysis

TrendBullish
RSI67.5
Support€6.16
Resistance€6.66
MA 20€6.44
MA 50€6.08
MA 200€5.48
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value€8.09
Target Price€5.98
Upside/Downside-9.60%
GradeUndervalued
TypeBlend
Dividend Yield4.67%

Risk Assessment

Beta0.13
Volatility20.48%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.